Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Authors
Category Primary study
ConferenceBlood
Year 2021
This article has no abstract
Epistemonikos ID: dcf3706ac1d59d69653bee4912dd1e593887cefe
First added on: Feb 13, 2025